Cancellation of the Women’s Health Initiative (WHI)

The National Institutes of Health (NIH) has announced the cancellation of the Women’s Health Initiative (WHI), its first and largest study centered on women’s health [read the announcement here]. Launched in 1991, the WHI has been instrumental in advancing understanding of women’s health issues, including cardiovascular disease, cancer, and osteoporosis. The decision to terminate the study has raised concerns among researchers and advocates about the future of women’s health research in the United States.​

NHLBI’s Role in Supporting the Women’s Health Initiative
The National Heart, Lung, and Blood Institute (NHLBI), part of the NIH, has been the primary sponsor and steward of the WHI since its launch. Designed as one of the largest and most comprehensive research programs focused on women’s health in the United States, the WHI aimed to address the leading causes of death and disability among postmenopausal women, including cardiovascular disease, cancer, and osteoporosis.

Over three decades, NHLBI provided sustained funding and scientific oversight for the WHI’s landmark clinical trials and observational studies. These efforts have generated critical data that reshaped medical guidelines, notably in hormone replacement therapy, and informed public health strategies affecting millions of women.

NHLBI’s support also extended to developing an extensive biospecimen and data repository, fostering ongoing research across various institutions. The WHI’s legacy continues to influence policy and healthcare despite the recent decision to discontinue funding, which has sparked debate over the NIH’s commitment to women’s health research.

WHI’s Key Accomplishments:

• NHLBI’s Framingham Heart Study, launched in 1948, was designed from the beginning to include men and women.
• The Women’s Ischemia Syndrome Evaluation (WISE) study advanced the understanding of heart disease in women, leading to improved diagnosis and treatment.
• The NHLBI-sponsored Women’s Health Initiative found that hormone replacement therapy does not protect older postmenopausal women from cardiovascular disease.
• The CHAP trial found that pregnant women treated with high blood pressure medicine present before or during the first 20 weeks of pregnancy had better outcomes.
• NHLBI research is studying the causes and risk factors for preeclampsia and how the condition affects women’s future cardiovascular disease risk.
• An NHLBI-funded trial showed that sirolimus is an effective treatment for lymphangioleiomyomatosis (LAM), a rare lung disease that affects women.

Sources
– https://www.nhlbi.nih.gov/science/womens-health
– https://www.whi.org/md/news/whi-funding-announcement
– https://www.science.org/content/article/nih-cancels-its-first-and-largest-study-centered-women

---